A Phase 2 interventional study of Low-dose Colchicine at 0.5mg daily and Usual Care in Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function and Vascular Calcification, sponsored by University of Texas Southwestern Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 30 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by University of Texas Southwestern Medical Center · Phase 2, Interventional, and Treatment
This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease (CKD) and existing coronary artery calcification. Sixty participants will be randomized 1:1 to received LoDoCo plus usual care or usual care lone and followed for 24 months.
The primary objective is to evaluate the effect of LoDoCo on CAC progression measured by ECG-gates noncontrast cardiac computed tomography (CT). Exploratory outcomes include valvular calcification, bone mineral density, inflammatory, vascular, and miner-bone biomarkers, cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures, kidney biomarkers, and participant-reported measures of treatment acceptability, adherence, and adverse effects.
The investigators will conduct a randomized, open-label, outcome-blinded, clinical trial in 60 adults with chronic kidney disease (CKD) and existing coronary artery calcification (CAC) Agatston scores of ≥100-1000. Participants will be randomized 1:1 to receive low-dose Colchicine (LoDoCo) plus usual care or usual care alone for 24 months.
The primary objective is to evaluate the effect of LoDoCo on CAC progression over 24 months. CAC will be assessed by ECG-gated noncontrast cardiac computed tomography (CT). Outcomes will include Agatston score and calcium volume. The study will estimate variance, baseline-to-follow-up correlations, and other parameters needed to inform future sample size, treatment duration, and endpoint selection.
Exploratory objectives include evaluating the effects of LoDoCo on aortic valve and mitral annular calcification, CT-derived vertebral bone mineral density, inflammatory biomarkers, vascular calcification biomarkers, and miner-bone metabolism biomarkers. Additional exploratory analyses will examine cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures including ankle-brachial index (ABI) and toe-brachial index (TBI), and kidney outcomes including albumin-creatine ratio (uACR) and estimated glomerular filtration rate (eGFR).
Participant experience with LoDoCo will also be evaluated through assessment of treatment acceptability, adherence, adverse effects, and barriers and facilitators to study participation and retention.
Participants will be followed at baseline, 6 months, 12 months, 18 months, and 24 months for data collection. Participants assigned to the intervention group will undergo additional safety monitoring, including laboratory assessments, throughout the study period.
73 studies on the registry are indexed under Chronic Kidney Disease-Mineral and Bone Disorder; 20 are open to participants now.
This study's planned enrollment of 60 is above the median of 54 across 34 interventional studies indexed under Chronic Kidney Disease-Mineral and Bone Disorder.
Browse Chronic Kidney Disease-Mineral and Bone Disorder studies →University of Texas Southwestern Medical Center is the lead sponsor of 1,010 studies on the registry; 199 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive low-dose Colchicine (LoDoCo) in addition to usual care.
Drug: Low-dose Colchicine at 0.5mg daily · Other: Usual Care
Participants will receive usual care alone.
Other: Usual Care
Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.
Also known as: LoDoCo
Participants will receive usual care according to standard clinical practice and treating physician discretion.
Change in Coronary Artery Calcification Agatston Scores
Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Coronary artery calcification will be quantified using the Coronary Artery Calcium (CAC) Agatston Score. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.
Time frame: Baseline, 12 months, 24 months
Change in Coronary Artery Calcification Volume Scores
Change in Coronary Artery Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Aortic Valve Calcification Agatston Scores
Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Aortic valve calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the aortic valve. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Aortic Valve Calcification Volume Scores
Change in Aortic Valve Calcification volume (mm3) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Agatston Scores
Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Mitral annular calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the mitral valve annulus. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Volume Scores
Change in Mitral Annular Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Vertebral Bone Mineral Density (BMD)
Change in vertebral BMD (mg/cm³) will be measured from ECG-gated non-contrast computer tomography (CT) using validated CT-based densitometry methods. BMD will be quantified within the vertebral bodies. Vertebral MBD values range from \<80mg/cm³ (very low), 80-120mg/cm³ (low), and \>120 mg/cm³ (normal). Lower TBI values are associated with worse outcomes.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in C-Reactive Protein (CRP) Levels
Circulating CRP (mg/L) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-1 beta (IL-1β) Levels
Circulating IL-1β levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-6 (IL-6) Levels
Circulating IL-6 levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 18 months
Exploratory: Change in Interleukin-18 (IL-18) Levels
Circulating IL-18 levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Tumor Necrosis Factor alpha
Circulating TNF-a levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-17 (IL-17) Levels
Circulating IL-17 levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Monocyte Chemoattractant Protein-1 (MCP-1) levels
Circulating MCP-1 levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Serum Klotho Levels
Circulating klotho levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Fetuin A Levels
Circulating fetuin A levels (ng/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Osteopontin Levels
Circulating osteopontin levels (ng/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-2 (BMP-2) Levels
Circulating BMP-2 levels (ng/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-4 (BMP-4) Levels
Circulating BMP-4 levels (ng/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-7 (BMP-7) Levels
Circulating BMP-7 levels (ng/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Serum Phosphate levels
Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Serum Calcium Levels
Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Parathyroid Hormone (PTH) levels
Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Bone-Specific Alkaline Phosphatase (BSAP) Levels
Circulating serum BSAP levels (ug/L) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Fibroblast Growth Factor 23 (FGF23) Levels
Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Wnt Inhibitory Factor-1 Levels
Circulating Wnt Inhibitory Factor-1 (pg/dL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Intact N-Terminal Propeptide of Type I Procollagen (P1NP) Levels
Circulating P1NP levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Sclerostin Levels
Circulating sclerostin levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) Levels
Circulating TRAP-5b levels (U/L) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in National Institutes of Health (NIH) Toolbox Fluid Cognition Composite Standard Score
The NIH Toolbox Fluid Cognition Composite score assesses cognitive functions involved in processing and responding to new information, including attention, executive function, episodic memory, processing speed, and working memory. The age-adjusted Fluid Cognition Composite Standard Score is derived from participant performance on NIH Toolbox cognitive assessments and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Scores of 70 or lower indicate significant impairment, scores around 85 are below average, scores around 100 are average, scores around 115 are above average, and scores around 130 are superior. Higher scores indicate better cognitive performance.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Executive Function
Executive function will be assessed using the NIH Toolbox Dimensional Change Card Sort Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better executive functioning.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Attention/Inhibitory Control
Attention and inhibitory control will be assessed using the NIH Toolbox Flanker Inhibitory Control Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better attention and inhibitory control.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Processing Speed
Processing speed will be assessed using the NIH Toolbox Pattern Comparison Processing Speed test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better processing speed.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Working Memory
Working memory will be assessed using the NIH Toolbox List Sorting Working Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better working memory.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Episodic Memory
Episodic memory will be assessed using the NIH Toolbox Picture Sequence Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better episodic memory.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Language/Vocabulary
Language/Vocabulary will be assessed using the NIH Toolbox Picture Vocabulary Test and Oral Reading Recognition tests. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better language ability.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Southwestern Assessment of Processing Speed (SWAPS) Score
The SWAPS will be used to assess processing speed. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better processing speed performance.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Texas Card Sorting Test (TCST) Score
The TCST will be used to assess executive functioning, including cognitive flexibility and concept formation. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better executive functioning.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Phosphorylated tau 217 (p-tau217) levels
Circulating p-tau217 levels (pg/mL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Amyloid-beta 42/40 ratio (Aβ42/40) Levels
Circulating Aβ42 and Aβ40 levels (pg/mL) will be measured using standard clinical laboratory assays and the Aβ42/40 ratio calculated from these measurements and reported as a unitless ratio.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Ankle-Brachial Index (ABI)
ABI will be measured using semi-automated validated device (simpleABI-600CL). ABI values range from ≤0.90 (Peripheral artery disease), 0.91-0.99 (borderline), 1.00-1.40 (normal).ABI values \>1.40 indicate non-compressible arteries, suggestive of arterial stiffness or medial calcification. Both ABI values ≤0.90 and \>1.40 are associated with worse outcomes.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Toe-Brachial Index (TBI)
TBI will be measured using semi-automated validated device (simpleABI-600CL). TBI values range from ≥0.70 (normal), 0.64-0.69 (borderline), and \<0.40-0.50 (severe distal arterial disease/critical ischemia range). TBI values \<0.70 is a commonly used threshold suggestive of peripheral artery disease. Lower TBI values are associated with worse outcomes.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Percentage of Participants with Ankle-Brachial Index (ABI) ≤0.9 or >1.4
ABI will be measured using semi-automated validated device (simpleABI-600CL). The percentage (%) of participants with an ABI ≤0.9, indicative of peripheral arterial disease, or an ABI \>1.4, indicative of non-compressible arteries suggestive of arterial stiffness or medial calcification will be determined. Higher percentages indicate a greater proportion of participants with abnormal ABI findings.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Urine Albumin-to-Creatine Ratio (uACR)
Circulating urinary albumin and creatine levels (mg/dL) will be measured using standard clinical laboratory assays.
Time frame: Baseline, 12 months, 24 months
Exploratory: Change in Estimated Glomerular Filtration Rate (eGFR)
eGFR values (mL/min/1.73m2) will be calculated using the NKF-ASN CKD-Epi refit formula.
Time frame: Baseline, 12 months, 24 months
Plan to share: Yes — IRB approval is required before sharing IPD.
Supporting information: Study protocol, Statistical analysis plan
Start is estimated for Oct 2026; primary completion for May 2029, 30 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Jul 2026 → Oct 2026, primary completion Dec 2027 → May 2029 and completion Dec 2027 → May 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Chronic Kidney Disease-Mineral and Bone Disorder →
University of Texas Southwestern Medical Center →